Boston, Massachusetts — October 29, 2026
CervoMed Inc. announced the publication of two peer-reviewed research articles providing additional clinical and scientific evidence supporting the development of neflamapimod, an investigational oral treatment for dementia with Lewy bodies (DLB). The first publication, in Alzheimer’s Research & Therapy, presents findings from the placebo-controlled phase of the company’s 159-patient Phase 2b RewinD-LB clinical trial. The second, published in Cells, reports preclinical and clinical research showing that neflamapimod inhibits interleukin-1 beta (IL-1β) signalling, a pathway associated with neuroinflammation and cognitive decline. Although the Phase 2b study did not confirm the earlier Phase 2a results on its primary endpoint in the overall intention-to-treat population, analyses identified potential treatment benefits in patients without Alzheimer’s disease co-pathology and in participants with higher drug exposure. Together, the publications provide further evidence to guide the candidate’s clinical development while highlighting the need for additional confirmatory studies.
Phase 2b RewinD-LB Results Identify Potential Benefit in Selected Patients
The Alzheimer’s Research & Therapy publication reports results from the placebo-controlled phase of the RewinD-LB Phase 2b trial, which evaluated oral neflamapimod at 40 mg three times daily in 159 patients with DLB. The study did not meet its primary endpoint, change in the Clinical Dementia Rating Sum of Boxes (CDR-SB), across the full intention-to-treat population. However, subgroup analyses indicated a greater potential treatment effect among patients without Alzheimer’s disease co-pathology, identified using low blood phosphorylated tau 181 (pTau181) levels. In patients with pTau181 below 23 pg/mL, the placebo-adjusted CDR-SB difference was −0.51 points, while the subgroup below 21 pg/mL showed a difference of −0.70 points. Both findings had confidence intervals that included zero, so they should be interpreted as suggestive rather than definitive evidence. An MRI substudy also demonstrated a statistically significant increase in right basal forebrain volume compared with placebo, providing an imaging finding consistent with a potential effect on underlying disease processes. These results were reported to replicate aspects of the earlier Phase 2a AscenD-LB findings, particularly in patients without Alzheimer’s co-pathology.
Drug Exposure and Neuroinflammation Findings Support Further Investigation
Additional analyses suggested that neflamapimod exposure may influence clinical response. Participants with blood drug concentrations above the study median of 3.64 ng/mL showed CDR-SB treatment effects comparable to those observed in the earlier Phase 2a trial, whereas participants below the median did not show similar effects. CervoMed indicated that lower-than-intended drug exposure from the capsule formulation used in the placebo-controlled phase may have contributed to the lack of confirmation of the primary endpoint in the overall population. The Cells publication provides complementary mechanistic evidence, reporting that neflamapimod inhibited IL-1β-induced IL-6 and IL-8 production in human peripheral blood mononuclear cells, with an EC50 of approximately 3 ng/mL. Clinical biomarker findings included reductions in cerebrospinal fluid IL-6 and IL-8 in patients with early Alzheimer’s disease, alongside changes in plasma biomarkers in DLB patients. Pharmacokinetic and pharmacodynamic analyses identified a trough plasma concentration threshold of approximately 4 ng/mL associated with pharmacological activity. CervoMed’s CEO, Dr. John Alam, said the alignment of clinical, biomarker and imaging findings supports further development and the evaluation of a 100 mg twice-daily tablet formulation, which the company projects could achieve target trough concentrations in more than 90% of participants. These projections will require clinical validation.
Advertisement
Favourable Safety Profile and Next Steps in DLB Development
Neflamapimod was generally well tolerated in the placebo-controlled Phase 2b study. Discontinuations due to adverse events occurred in 2.5% of participants receiving neflamapimod and 1.3% receiving placebo. One event in a neflamapimod-treated participant involved transient liver enzyme elevations that normalised after treatment discontinuation; the participant had a pre-existing liver condition. The study also included a 32-week extension phase, with further results expected in a separate publication. CervoMed is continuing to evaluate neflamapimod for DLB and other age-related neurological conditions, including recovery after ischemic stroke and primary progressive aphasia. The company has previously reported alignment with the US Food and Drug Administration on a potential registration pathway for DLB and is seeking a strategic partner to advance the candidate into Phase 3 development. Neflamapimod remains investigational, and there are currently no approved treatments specifically for DLB in the United States or European Union. The two publications strengthen the scientific rationale for further evaluation, but the Phase 2b primary endpoint result means that additional clinical evidence will be essential to establish whether the candidate can provide meaningful and reproducible benefits for patients and caregivers.
Source: CervoMed ,Press release
